Cargando…
CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 nuclease system has allowed the generation of disease models and the development of therapeutic approaches for many genetic and non-genetic disorders. However, the generation of large genomic rearrangements has raised safety...
Autores principales: | Amendola, Mario, Brusson, Mégane, Miccio, Annarita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585945/ https://www.ncbi.nlm.nih.gov/pubmed/36048170 http://dx.doi.org/10.1093/stcltm/szac064 |
Ejemplares similares
-
Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing
por: Leibowitz, Mitchell L., et al.
Publicado: (2021) -
Base and Prime Editing Technologies for Blood Disorders
por: Antoniou, Panagiotis, et al.
Publicado: (2021) -
CRISPR/Cas9-induced DNA breaks trigger crossover, chromosomal loss, and chromothripsis-like rearrangements
por: Samach, Aviva, et al.
Publicado: (2023) -
CRISPR/Cas9 and TALE: beyond cut and paste
por: Deng, Liping, et al.
Publicado: (2015) -
A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use
por: Jiang, Long, et al.
Publicado: (2022)